Fundraising Fox
Sonalasense
Berkeley, US · Founded 2019 · New York corporation · 1 known investors
Find your way into Sonalasense
Sign up to see every warm intro you have to Sonalasense
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sonalasense team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SonALAsense develops Sonodynamic Therapy (SDT), a non-invasive drug-device cancer treatment combining its SONALA-001 drug with an ultrasound device to treat deadly cancers such as High-Grade Gliomas and DIPG. The company is running Phase 0/1 and Phase 1/2 clinical trials and targets patients with brain tumors that typically require surgery.
Founders & leadership
Investors · 1
Reported raises · per SEC filings
Form D private placements$34.8M disclosed across 4 rounds · 2019–2023
▶$9.8MraisedNov 2023 · 30 investors · BiotechnologyRule 506(b)
- MARK P. DE SOUZAExecutive Officer, Director
- STUART MARCUSExecutive Officer, Director
- VINCENT SAIDirector
- Offering amount
- $15M
- Amount sold
- $9.8M
- First sale
- Feb 2023
- Incorporated
- Corporation, New York, 2019
- Federal exemptions
- 06b
▶$20.1MraisedJan 2022 · 30 investors · BiotechnologyRule 506(b)
- Stuart MarcusExecutive Officer, Director
- Mark P. de SouzaExecutive Officer, Director
- Offering amount
- $30.1M
- Amount sold
- $20.1M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$3.9MraisedFeb 2021 · 26 investors · BiotechnologyRule 506(b)
- Stuart MarcusExecutive Officer, Director
- Mark P. de SouzaExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $3.9M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1000KraisedSep 2020 · 13 investors · BiotechnologyRule 506(b)
- Stuart MarcusExecutive Officer, Director
- Mark P. de SouzaExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1000K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Sonalasense.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $694.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Sonalasense do?
- SonALAsense develops Sonodynamic Therapy (SDT), a non-invasive drug-device cancer treatment combining its SONALA-001 drug with an ultrasound device to treat deadly cancers such as High-Grade Gliomas and DIPG. The company is running Phase 0/1 and Phase 1/2 clinical trials and targets patients with brain tumors that typically require surgery.
- Who are Sonalasense's investors?
- Sonalasense's investors include Keiretsu Forum.
- How much funding has Sonalasense raised?
- Sonalasense has disclosed $34.8M raised across 4 rounds.
- Where is Sonalasense headquartered?
- Sonalasense is headquartered in Berkeley, US.